Boston Scientific (BSX) Cash from Investing Activities (2009 - 2026)

Boston Scientific (BSX) has 18 years of Cash from Investing Activities data on file, last reported at -$591.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 18.2% year-over-year to -$591.0 million; the trailing twelve-month figure through Mar 2026 stood at -$2.7 billion (up 53.73% YoY), and the FY2025 full-year result was -$2.6 billion, up 53.58% from the prior year.
• Cash from Investing Activities retreated to -$591.0 million in Q1 2026, from -$512.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of -$29.0 million in Q2 2022 to a low of -$3.7 billion in Q4 2024.
• A 5-year average of -$794.3 million and a median of -$502.0 million in 2025 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities tumbled 2796.55% in 2023 and surged 86.18% in 2025, its largest moves.
• Tracing BSX's Cash from Investing Activities over 5 years: stood at -$183.0 million in 2022, then slumped by 475.41% to -$1.1 billion in 2023, then sank by 251.76% to -$3.7 billion in 2024, then surged by 86.18% to -$512.0 million in 2025, then retreated by 15.43% to -$591.0 million in 2026.
• Business Quant data shows BSX's Cash from Investing Activities at -$591.0 million in Q1 2026, -$512.0 million in Q4 2025, and -$502.0 million in Q3 2025.